|
See related Micardis tab information |
|
|
|
Manufacturer |
Boehringer Ingelheim |
|
Distributor |
Hong Kong: Zuellig/Macau: Agencia Lei Va Hong |
|
Contents |
Telmisartan |
|
Indications |
Treatment of essential HTN. Reduction of CV morbidity in patients w/ manifest atherothrombotic CV disease (history of CHD, stroke or peripheral arterial disease) or type 2 DM w/ documented target organ damage.
Click to view Micardis detailed prescribing infomation |
|
Dosage |
Adult Treatment of essential HTN 40 mg once daily. Max: 80 mg once daily. Prevention of CV morbidity 80 mg once daily. Severe renal impairment Initially 20 mg. Mild to moderate hepatic impairment Max: 40 mg once daily.
Click to view Micardis detailed prescribing infomation |
|
Overdosage |
View Micardis overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Pregnancy (2nd & 3rd trimesters), lactation. Biliary obstruction, severe hepatic impairment.
Click to view Micardis detailed prescribing infomation |
|
Special Precautions |
Renovascular HTN. Monitor K & creatinine levels in patients w/ impaired renal function. Intravascular hypovolaemia should be corrected prior to treatment. Severe CHF, primary aldosteronism, aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy. Monitor serum K in patients at risk of hyperkalaemia. Hepatic impairment. Rare hereditary condition of fructose intolerance. Childn <18 yr.
Click to view Micardis detailed prescribing infomation |
|
Adverse Drug Reactions |
UTI, upper resp tract infections, anaemia, hyperkalaemia, insomnia, depression, syncope, vertigo, bradycardia, hypotension, orthostatic hypotension, dyspnoea, abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting, hyperhidrosis, pruritus, rash, back & chest pain, muscle spasms, myalgia, renal impairment, asthenia, increased blood creatinine.
View ADR Monitoring Form |
|
Drug Interactions |
K supplements, K-containing salt substitutes, K-sparing diuretics, ACE inhibitors, AIIA, NSAIDs, heparin, digoxin, lithium. May increase hypotensive effect of other antihypertensive agents.
View more drug interactions with Micardis |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Micardis storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Micardis mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Micardis tablet |
|
Micardis 40 mg x 30's |
 |
|
Micardis 80 mg x 30's |
 |
|
|
|
Manufacturer: |
Boehringer Ingelheim |
|
Distributor: |
Hong Kong: Zuellig
Macau: Agencia Lei Va Hong
|
|
|
|
